References
  1. B. R. Groveman et al., “Sporadic Creutzfeldt-Jakob disease prion infection of human cerebral organoids,” Acta Neuropathol. Commun., vol. 7, no. 1, pp. 1–12, 2019.
  2. A. Ladogana et al., “Mortality from Creutzfeldt–Jakob disease and related disorders in Europe, Australia, and Canada,” Neurology, vol. 64, no. 9, pp. 1586–1591, 2005.
  3. S. J. Collins et al., “Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease,” Brain, vol. 129, no. 9, pp. 2278–2287, 2006, doi: 10.1093/brain/awl159.
  4. A. Krasnianski et al., “Neuropsychological symptoms in sporadic Creutzfeldt-Jakob disease patients in Germany,” J. Alzheimer’s Dis., vol. 59, no. 1, pp. 329–337, 2017.
  5. [5] P. Brown, F. Cathala, P. Castaigne, and D. C. Gajdusek, “Creutzfeldt‐Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases,” Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc., vol. 20, no. 5, pp. 597–602, 1986.
  6. G. D. Rabinovici et al., “First symptom in sporadic Creutzfeldt–Jakob disease,” Neurology, vol. 66, no. 2, pp. 286–287, 2006.
  7. G. S. Young et al., “Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis,” Am. J. Neuroradiol., vol. 26, no. 6, pp. 1551–1562, 2005.
  8. J. N. Trollor, X. Chen, and P. S. Sachdev, “Neuroleptic malignant syndrome associated with atypical antipsychotic drugs,” CNS Drugs, vol. 23, no. 6, pp. 477–492, 2009.
  9. T. E. Bertorini, “Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome,” Neurol. Clin., vol. 15, no. 3, pp. 649–671, 1997.
  10. J. Latham, D. Campbell, and W. Nichols, “How much can exercise raise creatine kinase level—and does it matter?,” Clin. Inq. 2008, 2008.
  11. R. J. Gurrera, “Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome,” Am. J. Psychiatry, vol. 156, no. 2, pp. 169–180, 1999.
  12. Centers for disease control and prevention, “Diagnostic Criteria | Creutzfeldt-Jakob Disease, Classic (CJD) | Prion Disease | CDC,” 2018. https://www.cdc.gov/prions/cjd/diagnostic-criteria.html (accessed Apr. 19, 2021).
  13. M. D. Geschwind, “Rapidly progressive dementia,” Contin. Lifelong Learn. Neurol., vol. 22, no. 2 Dementia, p. 510, 2016.
  14. A. G. Osborn, G. L. Hedlund, and K. L. Salzman, Osborn’s Brain E-Book. Elsevier Health Sciences, 2017.
  15. D. C. Fragoso et al., “Imaging of Creutzfeldt-Jakob disease: imaging patterns and their differential diagnosis,” Radiographics, vol. 37, no. 1, pp. 234–257, 2017.
  16. D. P. Seitz and S. S. Gill, “Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature,” Psychosomatics, vol. 50, no. 1, pp. 8–15, 2009.
  17. J. Mesquita and L. Siva, “Fatal neuroleptic malignant syndrome induced by clozapine in Parkinson’s psychosis,” J. Neuropsychiatry Clin. Neurosci., vol. 26, no. 1, pp. E34–E34, 2014.
  18. A. W. Lemstra, N. Schoenmaker, A. J. M. Rozemuller-Kwakkel, and W. A. van Gool, “The association of neuroleptic sensitivity in Lewy body disease with a false positive clinical diagnosis of Creutzfeldt-Jakob disease,” Int. J. Geriatr. Psychiatry, vol. 21, no. 11, pp. 1031–1035, 2006, doi: 10.1002/gps.1602.
  19. J. Yang, H. Kuang, Q. Wang, J. Liu, X. Chen, and H. Shang, “Analysis of Chinese patients with sporadic Creutzfeldt-Jakob disease,” Prion, vol. 14, no. 1, pp. 137–142, 2020.
  20. D. N. Manners et al., “Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease,” Neurology, vol. 72, no. 16, pp. 1425–1431, 2009.
  21. C. Carswell et al., “MRI findings are often missed in the diagnosis of Creutzfeldt-Jakob disease,” BMC Neurol., vol. 12, no. 1, pp. 1–5, 2012.
  22. M. Pocchiari et al., “Predictors of survival in sporadic Creutzfeldt–Jakob disease and other human transmissible spongiform encephalopathies,” Brain, vol. 127, no. 10, pp. 2348–2359, 2004.
  23. E. Nakatani et al., “Specific clinical signs and symptoms are predictive of clinical course in sporadic Creutzfeldt− Jakob disease,” Eur. J. Neurol., vol. 23, no. 9, pp. 1455–1462, 2016.
  24. F. Llorens et al., “A prognostic model for overall survival in sporadic Creutzfeldt‐Jakob disease,” Alzheimer’s Dement., vol. 16, no. 10, pp. 1438–1447, 2020.